{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:34:30Z","timestamp":1764102870667},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.rmr.2016.07.006","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T03:15:24Z","timestamp":1486610124000},"page":"121-133","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["M\u00e9canismes d\u2019action de l\u2019omalizumab\u00a0: au-del\u00e0 de l\u2019action anti-IgE"],"prefix":"10.1016","volume":"34","author":[{"given":"J.-M.","family":"Perotin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Barnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2016.07.006_bib0445","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy: INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0450","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0455","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1710-1492-9-47","article-title":"Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting","volume":"9","author":"Braunstahl","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0460","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1378\/chest.12-1372","article-title":"Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma","volume":"143","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.07.006_bib0465","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A phase II, randomized, doubleblind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0470","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nri1996","article-title":"Steady-state and inflammatory dendritic-cell development","volume":"7","author":"Shortman","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0475","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1185\/03007995.2011.620950","article-title":"Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients","volume":"27","author":"Siergiejko","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rmr.2016.07.006_bib0480","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1752-699X.2011.00263.x","article-title":"Omalizumab in patients with severe asthma: the XCLUSIVE study","volume":"6","author":"Schumann","year":"2012","journal-title":"Clin Respir J"},{"key":"10.1016\/j.rmr.2016.07.006_bib0485","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.rmed.2008.06.002","article-title":"Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study","volume":"102","author":"Niven","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0490","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmr.2015.07.008","article-title":"Omalizumab\u00a0: qu\u2019avons-nous appris apr\u00e8s 10\u00a0ans d\u2019utilisation\u00a0?","volume":"33","author":"Pradere","year":"2016","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2016.07.006_bib0495","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0500","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0162-3109(00)00229-0","article-title":"Immunotherapy approach to allergic disease","volume":"48","author":"Fick","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.rmr.2016.07.006_bib0505","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0510","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2003.11.044","article-title":"Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils","volume":"113","author":"Lin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0515","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000070434","article-title":"Immunological and clinical changes in allergic asthmatics following treatment with omalizumab","volume":"131","author":"Noga","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0520","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaci.2009.09.012","article-title":"Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge","volume":"125","author":"Eckman","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0525","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/all.12375","article-title":"Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children","volume":"69","author":"Hill","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0530","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1164\/ajrccm.155.6.9196083","article-title":"Inhibitory effects of an anti-IgE antibody E25\u00a0on allergen-induced early asthmatic response","volume":"155","author":"Boulet","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0535","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0540","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1398-9995.2008.01881.x","article-title":"Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment","volume":"64","author":"van Rensen","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0545","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000339243","article-title":"Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma","volume":"160","author":"Zielen","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0550","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1398-9995.2011.02546.x","article-title":"Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein","volume":"66","author":"Eggel","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0555","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12325-016-0287-8","article-title":"Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, an anti-IgE monoclonal antibody, in subjects with atopy: a phase I study","volume":"33","author":"Sheldon","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.rmr.2016.07.006_bib0560","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaip.2014.02.001","article-title":"Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"2","author":"Tsabouri","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2016.07.006_bib0565","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0570","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1084\/jem.175.5.1285","article-title":"Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI)","volume":"175","author":"Bieber","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0575","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00018-015-1870-x","article-title":"The role of FcepsilonRI expressed in dendritic cells and monocytes","volume":"72","author":"Shin","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.rmr.2016.07.006_bib0580","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2010.01.020","article-title":"Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways","volume":"125","author":"Chand","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0585","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.rmed.2010.07.011","article-title":"Omalizumab-induced decrease of Fc\u025bRI expression in patients with severe allergic asthma","volume":"104","author":"Chanez","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0590","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","article-title":"Omalizumab treatment downregulates dendritic cell FcepsilonRI expression","volume":"112","author":"Prussin","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0595","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1183\/09031936.00036307","article-title":"Airway dendritic cell phenotypes in inflammatory diseases of the human lung","volume":"30","author":"Lommatzsch","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.07.006_bib0600","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.4049\/jimmunol.175.9.5724","article-title":"TLR9- and FcepsilonRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression","volume":"175","author":"Schroeder","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0605","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2222.2008.02954.x","article-title":"Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-alpha via Toll-like receptor 9","volume":"38","author":"Tversky","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0610","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0615","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1365-2222.2006.02578.x","article-title":"CD2\u00a0identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of Fc epsilon RI","volume":"36","author":"Cheng","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0620","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0625","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaci.2009.11.022","article-title":"Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma","volume":"125","author":"Massanari","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0630","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000350852","article-title":"Omalizumab attenuates airway inflammation and interleukin-5\u00a0production by mononuclear cells in patients with severe allergic asthma","volume":"161","author":"Takaku","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0635","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2006.02.028","article-title":"Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma","volume":"117","author":"Noga","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0640","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1398-9995.2006.01180.x","article-title":"Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma","volume":"61","author":"Hanf","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0645","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/pai.12508","article-title":"Effects of omalizumab on T lymphocyte function in inner-city children with asthma","volume":"27","author":"Gruchalla","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0650","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2045-7022-3-29","article-title":"Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells","volume":"3","author":"Chan","year":"2013","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0655","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","article-title":"Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE","volume":"72","author":"Lowe","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0660","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1081-1206(10)61170-2","article-title":"Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells","volume":"95","author":"Huang","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0665","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000319205","article-title":"RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy","volume":"154","author":"Zietkowski","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0670","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/thx.54.9.825","article-title":"Cytokines in asthma","volume":"54","author":"Chung","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.07.006_bib0675","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.anai.2009.11.022","article-title":"The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells","volume":"104","author":"Roth","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0680","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2009.10.021","article-title":"Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0685","first-page":"177","article-title":"Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma","volume":"25","author":"Shimizu","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.rmr.2016.07.006_bib0690","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1398-9995.2009.02201.x","article-title":"Effects of omalizumab on markers of inflammation in patients with allergic asthma","volume":"64","author":"Holgate","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0695","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.rmr.2013.11.001","article-title":"R\u00e9g\u00e9neration de l\u2019\u00e9pithelium des voies a\u00e9riennes","volume":"31","author":"Adam","year":"2014","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2016.07.006_bib0700","doi-asserted-by":"crossref","first-page":"e0136549","DOI":"10.1371\/journal.pone.0136549","article-title":"Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab","volume":"10","author":"Roth","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.rmr.2016.07.006_bib0705","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000334701","article-title":"Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma","volume":"83","author":"Hoshino","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2016.07.006_bib0710","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/039463201202500217","article-title":"Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients","volume":"25","author":"Riccio","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0715","doi-asserted-by":"crossref","first-page":"e56015","DOI":"10.1371\/journal.pone.0056015","article-title":"The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling","volume":"8","author":"Roth","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.rmr.2016.07.006_bib0720","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.imlet.2014.08.010","article-title":"Proteomics of bronchial biopsies: galectin-3\u00a0as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients","volume":"162","author":"Mauri","year":"2014","journal-title":"Immunol Lett"},{"key":"10.1016\/j.rmr.2016.07.006_bib0725","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/02770903.2012.757780","article-title":"Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry","volume":"50","author":"de Llano","year":"2013","journal-title":"J Asthma"},{"key":"10.1016\/j.rmr.2016.07.006_bib0730","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.07.006_bib0735","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2006.09.045","article-title":"Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma","volume":"119","author":"Takhar","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0740","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cea.12064","article-title":"Plasmacytoid dendritic cells in allergic asthma and the role of inhaled corticosteroid treatment","volume":"43","author":"Bratke","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0745","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.4049\/jimmunol.165.11.6037","article-title":"BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood","volume":"165","author":"Dzionek","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0750","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2003.09.011","article-title":"Human dendritic cell 1\u00a0and dendritic cell 2\u00a0subsets express FcepsilonRI: correlation with serum IgE and allergic asthma","volume":"112","author":"Foster","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0755","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1183\/09031936.00203412","article-title":"The plasmacytoid dendritic cell: at the cross-roads in asthma","volume":"43","author":"Lynch","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.07.006_bib0760","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/cea.12664","article-title":"The dendritic cell high-affinity IgE receptor is overexpressed both in asthma and severe COPD","volume":"46","author":"Stoll","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0765","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1164\/ajrccm.153.6.8665058","article-title":"High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma","volume":"153","author":"Humbert","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0770","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0775","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2500\/ajr.2007.21.3060","article-title":"The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study","volume":"21","author":"Penn","year":"2007","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0780","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhin09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.rmr.2016.07.006_bib0785","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jaci.2010.12.1085","article-title":"Omalizumab is effective in nonautoimmune urticaria","volume":"127","author":"Ferrer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0790","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1398-9995.2010.02472.x","article-title":"Omalizumab\u00a0\u2013\u00a0an effective and safe treatment of therapy-resistant chronic spontaneous urticaria","volume":"66","author":"Groffik","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0795","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0800","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0805","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/jid.2014.512","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1\u00a0antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0810","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0815","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2013.05.035","article-title":"Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective","volume":"69","author":"Lacombe Barrios","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0820","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1067\/mai.2003.1626","article-title":"Surface expression of Fc epsilon RI on Langerhans\u2019 cells of clinically uninvolved skin is associated with disease activity in atopic dermatitis, allergic asthma, and rhinitis","volume":"112","author":"Semper","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0825","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/1523-1747.ep12343596","article-title":"Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema","volume":"106","author":"Wollenberg","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0835","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000320233","article-title":"Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria","volume":"154","author":"Metz","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.rmr.2016.07.006_bib0840","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0845","first-page":"CD010288","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"9","author":"Jat","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2016.07.006_bib0850","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0855","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2016.07.006_bib0860","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.11-1881","article-title":"Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"142","author":"Kaya","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.07.006_bib0865","first-page":"272","article-title":"Anti-IgE in Churg-Strauss syndrome","volume":"64","author":"Giavina-Bianchi","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.07.006_bib0870","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2014.02.003","article-title":"Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control","volume":"108","author":"Molimard","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2016.07.006_bib0875","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1398-9995.2009.02144.x","article-title":"After 6\u00a0years with Xolair; a 3-year withdrawal follow-up","volume":"65","author":"Nopp","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2016.07.006_bib0440","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842516302431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842516302431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T04:39:56Z","timestamp":1692679196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842516302431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0761842516302431"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2016.07.006","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M\u00e9canismes d\u2019action de l\u2019omalizumab\u00a0: au-del\u00e0 de l\u2019action anti-IgE","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2016.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}